Actein

Actein is a cycloartane-type triterpene glycoside (β-D-xylopyranoside) from black cohosh rhizome that inhibits breast cancer cell proliferation (IC50 0.065 μM), suppresses VEGFR1 expression in endothelial cells, and modulates NF-κB, Ras/Raf/MEK/ERK, and JNK signaling pathways. In murine models, oral administration at 10–15 mg/kg for 28 days significantly reduced 4T1 breast tumor volume, lung and liver metastasis, and angiogenic gene expression, while increasing peripheral blood CD4/CD8 ratios.

Origin & History

Actein is a triterpene glycoside isolated from the rhizome of Actaea racemosa (black cohosh), a perennial flowering plant native to eastern North America, ranging from Nova Scotia to Georgia and westward to the Great Plains. The plant thrives in rich, moist woodland soils under partial to full shade, and was historically cultivated and harvested by Indigenous peoples of North America. The rhizome, which serves as the primary source of actein and related cycloartane triterpene glycosides, is typically collected in autumn after the plant reaches maturity.

Historical & Cultural Context

Black cohosh rhizome has been used medicinally by Indigenous North American peoples, including the Cherokee, Iroquois, and Algonquin nations, for centuries to treat gynecological conditions including menstrual irregularities, labor facilitation, and menopausal complaints, with the plant known by names such as 'squawroot' and 'black snakeroot.' European settlers adopted these uses by the 18th century, and black cohosh became a prominent constituent of patent medicines in the 19th century United States, notably in Lydia E. Pinkham's Vegetable Compound, a widely marketed women's tonic. The German Commission E formally approved black cohosh extract for menopausal symptoms in 1989, driving modern phytopharmaceutical research that led to the isolation and characterization of actein as a key bioactive triterpene glycoside alongside 23-epi-26-deoxyactein and cimicifugoside. The genus was reclassified from Cimicifuga to Actaea in the early 2000s based on molecular phylogenetic data, reflecting the compound's botanical nomenclature evolution from 'cimicifugoside' frameworks to 'actein'-centered nomenclature.

Health Benefits

- **Anti-Angiogenic Activity**: Actein suppresses VEGFR1 protein expression in human microvascular endothelial cells (HMEC-1) in a concentration-dependent manner (maximal effect at 20 μM), reducing pathological blood vessel formation that supports tumor growth.
- **Breast Cancer Cell Inhibition**: Actein selectively inhibits 4T1 murine breast cancer cell proliferation at an IC50 of 0.065 μM via ³H-thymidine incorporation assays, with activity observed at concentrations below 20 μM without measurable cytotoxicity to normal cells.
- **Menopausal Symptom Relief**: As a key bioactive constituent of black cohosh extracts, actein contributes to the traditional and contemporary use of the herb for alleviating hot flushes, night sweats, and hormonal imbalances associated with menopause.
- **Immunomodulation**: Oral actein administration in tumor-bearing mice elevated the peripheral blood CD4/CD8 T-cell ratio, suggesting enhancement of cell-mediated immune surveillance relevant to anti-tumor defense.
- **Metastasis Suppression**: In 4T1 syngeneic mouse tumor models, actein at 10–15 mg/kg orally for 28 days reduced both lung and liver metastatic burden, correlating with downregulation of Angiopoietin-2 (Ang2) and VEGFR1 mRNA in tumor tissue.
- **Chemotherapy Synergy**: Actein has demonstrated synergistic growth inhibition of human breast cancer cells when combined with standard chemotherapeutic agents, partially mediated through intracellular calcium release and concurrent modulation of survival signaling cascades.
- **Anti-Proliferative Signaling Modulation**: Actein downregulates phosphorylation of ERK and JNK kinases in endothelial cells at 5–20 μM (p < 0.05), disrupting mitogenic signaling that drives both tumor angiogenesis and cancer cell proliferation.

How It Works

Actein exerts its primary anti-proliferative and anti-angiogenic effects through simultaneous modulation of multiple intracellular signaling cascades: it suppresses the Ras/Raf/MEK/ERK pathway and inhibits JNK phosphorylation in endothelial cells at concentrations of 5–20 μM, reducing pro-survival and pro-migratory signaling. In breast cancer cells, actein induces intracellular calcium release and downregulates NF-κB transcriptional activity, thereby impairing inflammatory gene expression programs that support tumor survival and immune evasion. At the angiogenic level, actein concentration-dependently reduces VEGFR1 protein expression in HMEC-1 human microvascular endothelial cells and lowers mRNA levels of both VEGFR1 and Angiopoietin-2 (Ang2) within tumor microenvironments, limiting neovascularization necessary for tumor expansion. The immunomodulatory effect, evidenced by an increased CD4/CD8 ratio in vivo, suggests actein may additionally enhance adaptive immune responses through mechanisms not yet fully characterized at the molecular level.

Scientific Research

The current body of evidence for isolated actein is exclusively preclinical, comprising in vitro cell-based assays and in vivo murine studies, with no published human clinical trials specifically evaluating purified actein as of the available literature. In vitro work has employed standardized proliferation assays (³H-thymidine incorporation, MTT, trypan blue exclusion) across multiple cell lines including 4T1 murine breast cancer and HMEC-1 human endothelial cells, providing reproducible IC50 values and dose-response data. Animal studies utilized syngeneic 4T1 tumor implantation models with n=6 per group, oral gavage dosing (10–15 mg/kg for 28 days), and quantitative endpoints including tumor volume, metastatic nodule counts, gene expression (qPCR), and flow cytometric immune profiling, yielding statistically significant outcomes. Pharmacokinetic data from rat gavage (35.7 mg/kg) demonstrated detectable serum actein peaking at 2.4 μg/mL at 6 hours, confirming oral bioavailability, but human PK and dose translation remain unvalidated, placing overall evidence strength firmly at the preliminary preclinical stage.

Clinical Summary

No human clinical trials have been conducted using isolated, purified actein as the investigational compound; therefore, no clinical efficacy, safety, or dosing conclusions can be drawn for actein specifically in human populations. Human clinical data for menopausal symptom relief derives from trials of whole black cohosh extracts (e.g., isopropanolic extract Remifemin), in which actein is one of numerous bioactive constituents and not the isolated variable. Preclinical in vivo studies in mice provide the most structured efficacy data: oral actein at 10–15 mg/kg for 28 days produced statistically significant reductions in 4T1 tumor volume and metastatic colonization of lung and liver tissue (n=6/group, box-whisker analysis), with concomitant angiogenic gene suppression. Confidence in translating these findings to human clinical benefit is low pending Phase I/II trial data; the compound's potent in vitro IC50 (0.065 μM) and oral bioavailability in rodents provide a rational basis for future clinical investigation.

Nutritional Profile

Actein is a pure isolated bioactive compound (molecular formula C37H56O10, MW approximately 653 g/mol) and does not possess a conventional nutritional profile with macronutrients or micronutrients. As a cycloartane-type triterpene glycoside, it carries a β-D-xylopyranoside sugar moiety attached to a tetracyclic triterpene aglycone backbone, conferring amphiphilic properties that influence membrane interaction and oral absorption. In the context of whole black cohosh rhizome, the phytochemical matrix includes additional triterpene glycosides (23-epi-26-deoxyactein, cimicifugoside, cimiracemoside), isoflavones (formononetin, though disputed in some extracts), phenolic acids (caffeic acid, isoferulic acid), and alkaloids, all of which may contribute to bioavailability and synergistic activity. Oral bioavailability of actein in rats reaches a serum Cmax of approximately 2.4 μg/mL at Tmax of 6 hours following 35.7 mg/kg gavage, with metabolite contributions to observed biological effects not yet fully characterized.

Preparation & Dosage

- **Purified Research Compound**: Used exclusively in preclinical settings; no standardized human dose established. Murine oral doses of 10–15 mg/kg/day for 28 days produced anti-tumor effects; rat pharmacokinetic dose was 35.7 mg/kg.
- **Human Dose Estimate (Allometric Scaling, Unadjusted)**: Murine 10–15 mg/kg corresponds approximately to 0.8–1.2 mg/kg in humans using standard body surface area conversion, but this has not been validated clinically.
- **Black Cohosh Standardized Extract**: The most common human-available form containing actein; extracts are typically standardized to 2.5% triterpene glycosides (as 27-deoxyactein) per European Pharmacopoeia standards. Typical commercial dose: 40–80 mg extract (equivalent to ~8–40 mg crude rhizome) twice daily.
- **Aqueous Tincture/Maceration**: Traditional preparation method involving maceration or percolation of dried black cohosh rhizome in aqueous-ethanolic solvent; actein and 26-deoxyactein co-precipitate with protoanemonin analogues. Standardization of actein content in tinctures is inconsistent.
- **Hydrodistillation Extract**: Used in phytochemical research; yields variable actein concentrations depending on rhizome quality, geographic origin, and harvest timing.
- **Timing**: Black cohosh extracts are typically taken with meals to reduce gastrointestinal discomfort; duration of use for menopausal symptoms is conventionally limited to 6 months based on regulatory guidance, though evidence for this cutoff is not definitive.

Synergy & Pairings

Actein has demonstrated in vitro synergistic inhibition of breast cancer cell proliferation when combined with standard chemotherapeutic agents, with the proposed mechanism involving actein-mediated intracellular calcium mobilization and NF-κB suppression sensitizing cells to cytotoxic drug-induced apoptosis. Within black cohosh extracts, actein is believed to act synergistically with co-occurring triterpene glycosides such as 23-epi-26-deoxyactein and cimicifugoside, as well as phenolic acids like isoferulic acid, collectively producing broader estrogenic modulation and menopausal symptom relief than any single constituent alone. From a phytopharmacological perspective, combining standardized black cohosh extract with St. John's Wort (Hypericum perforatum) has been clinically evaluated for menopausal symptoms (hot flushes plus mood disturbance), representing the most evidence-supported combination stack containing actein-bearing material.

Safety & Interactions

At concentrations below 20 μM in cell-based assays, actein demonstrated no cytotoxicity as measured by MTT and trypan blue exclusion assays; however, systemic safety data in humans for isolated actein does not exist, as no human trials have been conducted. In the broader black cohosh context, the herb carries a regulatory advisory in several countries (including Germany's BfArM) recommending limiting use to 6 months due to rare reports of hepatotoxicity, though a causal relationship between black cohosh and liver injury remains debated and specific actein involvement is uncharacterized. Potential drug interactions relevant to actein-containing black cohosh extracts include additive effects with hormone therapies, cytochrome P450 3A4 substrates (black cohosh weakly inhibits CYP3A4), and theoretical potentiation of chemotherapy drugs given demonstrated synergy in preclinical models — requiring medical supervision in oncology contexts. Actein and black cohosh extracts are contraindicated or require caution in pregnancy (uterotonic historical use), active hormone-sensitive malignancies (estrogen receptor status debated), and patients with pre-existing hepatic conditions; use during lactation is not recommended due to insufficient safety data.